<DOC>
	<DOCNO>NCT00002862</DOCNO>
	<brief_summary>Phase I trial study effectiveness perillyl alcohol treat patient refractory cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Perillyl Alcohol Treating Patients With Refractory Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate maximum tolerate dose perillyl alcohol give chronically three time per day patient refractory malignancy . II . Describe toxic effect pharmacokinetics associated regimen . III . Evaluate antitumor activity perillyl alcohol patient . IV . Assess ability perillyl alcohol induce tumor differentiation reduce telomerase activity patient serial biopsy obtain . OUTLINE : This dose escalation study determine maximum tolerate dose perillyl alcohol . Groups 3-6 patient receive escalate dos oral perillyl alcohol three time per day maximum tolerate dose recommended phase II dose determine . Treatment assign dose continue disease progression unacceptable toxicity intervenes . Patients stable disease 8 week treatment remove study . Patients follow duration response survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Perilla alcohol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid malignancy lymphoma effective therapy exist Measurable evaluable disease No CNS metastasis unless stable least 4 week follow surgery and/or radiotherapy requirement anticonvulsant PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : At least 3 month ANC least 1,500 Platelets least 100,000 Bilirubin great 2.0 mg/dL AST le 2.5 time normal Creatinine clearance least 50 mL/min No concurrent cholesterollowering agent No active infection ( include HIV ) No concomitant medical condition precludes study compliance No pregnant nursing woman Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : At least 4 week since chemotherapy ( 6 week since nitrosoureas mitomycin ) At least 4 week since widefield radiotherapy Fully recover prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2000</verification_date>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>